Core Viewpoint - Rosen Law Firm is reminding investors of DexCom, Inc. about the upcoming deadline for a securities class action lawsuit, encouraging them to secure legal counsel before December 29, 2025 [1][2]. Group 1: Class Action Details - Investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors must act before the lead plaintiff deadline of December 29, 2025, and can join by submitting a form or contacting the law firm [3][6]. Group 2: Allegations Against DexCom - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5]. - It is claimed that DexCom overstated the enhancements and reliability of the G7 devices while downplaying the severity of the issues, leading to increased regulatory scrutiny and potential legal repercussions [5].

Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. alleging that the company made misleading statements regarding the reliability and safety of its G6 and G7 glucose monitoring devices, which were modified without FDA approval, leading to health risks for users [2][4]. Summary by Sections Lawsuit Details - The lawsuit claims that DexCom made unauthorized design changes to the G6 and G7 devices, which compromised their reliability and presented health risks to users [2]. - Allegations include overstating the enhancements and reliability of the G7, downplaying the severity of issues with the devices, and exposing the company to increased regulatory scrutiny and potential legal consequences [2]. Regulatory Concerns - On March 7, 2025, DexCom received a warning letter from the FDA regarding manufacturing and quality management issues, resulting in a share price drop of $7.12, or approximately 9.15%, from $77.84 to $70.72 [3]. - The FDA's published warning letter on March 25, 2025, confirmed that DexCom had adulterated its devices, leading to a further decline in share price by $1.77, or about 2.4%, from $75.32 to $73.55 [4]. Market Reactions - On September 8, 2025, Oppenheimer downgraded DexCom's rating to "perform" from "outperform," citing concerns over the G7's accuracy and performance, which caused a decline in share price by $2.51, or approximately 3.1%, from $80.51 to $78.00 [5]. - A report by Hunterbrook Media LLC on September 18, 2025, highlighted severe health risks associated with the G7 devices, linking them to hospitalizations and fatalities, resulting in a significant share price drop of $8.33, or about 11%, from $75.78 to $67.45 [7].

Core Viewpoint - Labaton Keller Sucharow LLP has filed a securities class action lawsuit against DexCom, Inc. and certain executives, alleging misleading statements regarding the reliability and safety of their continuous glucose monitoring systems [1][4]. Summary by Sections Lawsuit Details - The lawsuit was filed on November 25, 2025, on behalf of the Boston Retirement System against DexCom and its executives, asserting claims under the Securities Exchange Act of 1934 [1]. - The class period for the lawsuit is defined as January 8, 2024, to September 17, 2025 [1]. Allegations - The complaint alleges that DexCom made unauthorized design changes to its CGM products, which rendered them less reliable and posed health risks to users [4]. - It is claimed that these undisclosed issues led to increased regulatory scrutiny and negatively impacted the company's sales and public statements regarding product reliability [4]. Impact on Stock Price - Following disclosures about the accuracy problems of DexCom's CGM devices, the company's stock price fell by $8.99 per share, or 11.8%, closing at $67.45 on September 19, 2025 [5]. Legal Representation - The Boston Retirement System is represented by Labaton Keller Sucharow LLP, which has a strong reputation in securities litigation and manages over $4.5 trillion in assets [8].

Core Insights - DexCom Inc. is recognized as a strong stock within the QQQ index, despite recent price target reductions by analysts [1][2] - The company reported a significant year-over-year revenue increase, but faced challenges with gross margins [3][4] Financial Performance - DexCom achieved $1.21 billion in worldwide revenue for Q3 2025, reflecting a 22% increase year-over-year and 20% organic growth [3] - The company reported a net income of $242.5 million, translating to an earnings per share (EPS) of $0.61, marking the highest quarterly EPS in its history [3] Margin and Guidance Adjustments - Despite record revenue, DexCom's gross profit margin declined to 61.3% from 63% in Q3 2024, attributed to higher-than-expected scrap rates in manufacturing [4] - The company revised its 2025 non-GAAP gross profit margin guidance to approximately 61% while raising its overall revenue guidance to a range of $4.630 to $4.650 billion [4] Analyst Ratings - Morgan Stanley reduced its price target for DexCom to $63 from $89 but maintained an Overweight rating [1] - Truist lowered its price target to $82 from $94, citing a modest earnings beat and weaker-than-expected gross margins [2]

Core Viewpoint - Carillon Tower Advisers' "Carillon Eagle Mid Cap Growth Fund" reported a continued rally in equity markets during Q3 2025, driven by AI enthusiasm, limited inflationary effects from tariffs, and expectations for interest rate cuts from the U.S. Federal Reserve [1] Market Performance - The Russell Midcap Growth Index increased by 2.78%, while the Russell Midcap® Value Index outperformed with a gain of 6.16% during the same quarter [1] Sector Insights - The investor letter provided detailed insights on various sectors including Cyclicals, Healthcare, Information Technology, Financials, and Consumer sectors [1] Company Focus: DexCom, Inc. - DexCom, Inc. (NASDAQ:DXCM) is highlighted as a key stock, known for its continuous glucose monitoring systems, but has faced challenges including a one-month return of -10.14% and a 52-week loss of 20.18% [2][3] - As of November 24, 2025, DexCom's stock closed at $62.21, with a market capitalization of $24.396 billion [2] Financial Performance of DexCom - DexCom reported global revenue of $1.21 billion in Q3 2025, an increase from $994 million in Q3 2024, indicating a positive revenue trend despite recent challenges [4] Concerns and Market Position - There are concerns regarding accuracy issues with DexCom's latest G7 continuous glucose monitor, which may impact its brand and market share [3] - Despite the potential of DexCom as an investment, the company is viewed as having less upside compared to certain AI stocks [4]

NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM). Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/dexcom-inc-loss-submission-form-2/?id=178599&from=3 CLASS PERIOD: January 8, 2024 to ...

Core Viewpoint - Ademi & Fruchter LLP is investigating potential securities fraud claims against DexCom, Inc. due to inaccurate statements regarding its business operations and the quality of its products [1][2]. Group 1: Investigation Details - The investigation centers on DexCom's claims about its G7 blood glucose monitor, asserting it was of high quality and manufactured with FDA-approved materials [2]. - Reports indicate that DexCom altered the sensor membrane coating material from a third-party supplier to an in-house formulation without notifying the FDA or investors, which deviated from the FDA-approved formulation [2]. - The investigation period spans from January 8, 2024, to September 17, 2025 [2].

Accessibility StatementSkip Navigation Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: CONTACT:The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Email: [email protected] Phone: (646) 453-8903 NEW YORK, Nov. 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders ...

Investment Strategy - Investing in stocks for a long period, such as 30 years, can lead to significant wealth accumulation through compounding returns [1] - A well-defined strategy and commitment to endure market fluctuations are essential for investors [1][2] - Understanding personal risk tolerance and spreading investments across various asset classes and sectors is crucial for capitalizing on diverse growth opportunities [2] Healthcare Industry Opportunities - The healthcare industry offers substantial opportunities for notable portfolio returns over decades [3] - Vertex Pharmaceuticals and DexCom are highlighted as two companies with strong long-term growth potential in the healthcare sector [3] Vertex Pharmaceuticals - Vertex Pharmaceuticals holds a near monopoly in the cystic fibrosis drug market, generating significant revenue and strong free cash flow [4] - The company’s patents for key cystic fibrosis drugs extend into the late 2030s, providing a stable revenue foundation [4] - Vertex is expanding its portfolio beyond cystic fibrosis into other serious diseases, including a gene-editing therapy for sickle cell disease and a non-opioid pain management solution [5][6] - Vertex reported a total revenue of $3.08 billion for Q3 2025, an 11% year-over-year increase, with a net income of $1.1 billion [10] DexCom - DexCom is the leading manufacturer of continuous glucose monitoring devices, serving a growing global population with diabetes [11] - The company has a significant market share in the U.S. CGM market but has vast untapped opportunities, as less than 1% of Type 1 diabetics currently use CGM technology [12] - DexCom's revenue grew by 22% in Q3, with U.S. revenue increasing by 21% year-over-year and international revenue rising by 22% [16]

Core Viewpoint - Rosen Law Firm is encouraging investors of DexCom, Inc. to secure legal counsel before the December 29, 2025 deadline for a securities class action related to alleged misleading statements and health risks associated with the company's glucose monitoring systems [2][3][6]. Group 1: Class Action Details - The class action pertains to investors who purchased DexCom securities between July 26, 2024, and September 17, 2025 [2]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A lead plaintiff must file a motion with the court by December 29, 2025, to represent other class members [4]. Group 2: Allegations Against DexCom - The lawsuit claims that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [6]. - Defendants allegedly overstated the enhancements and reliability of the G7 devices while downplaying the severity of the issues [6]. - The situation has led to increased regulatory scrutiny and potential legal, reputational, and financial harm for DexCom [6]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company [5]. - The firm was ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [5]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [5].